<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315625</url>
  </required_header>
  <id_info>
    <org_study_id>150040</org_study_id>
    <secondary_id>15-C-0040</secondary_id>
    <nct_id>NCT02315625</nct_id>
  </id_info>
  <brief_title>Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery</brief_title>
  <official_title>A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Neuroendocrine tumors (NETs) come from cells of the hormonal and nervous systems. Some&#xD;
      people have surgery to shrink the tumor. Sometimes the tumors come back. Researchers think&#xD;
      that treatment with drugs based on knowing the defective gene might give better results.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      - To see if drugs selected based on the defective gene result in better tumor response. The&#xD;
      drugs are Sunitinib and Everolimus.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - People age 18 and older with an advanced low- or intermediate-grade gastrointestinal or&#xD;
      pancreatic neuroendocrine tumor.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with:&#xD;
&#xD;
        -  Medical history&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Scans&#xD;
&#xD;
        -  Blood, urine, and lab tests&#xD;
&#xD;
        -  The study team will see if participants should have surgery.&#xD;
&#xD;
        -  If yes, participants will:&#xD;
&#xD;
        -  Sign a separate consent&#xD;
&#xD;
        -  Have computed tomography (CT) scan before and after surgery&#xD;
&#xD;
        -  Have as much of the tumor removed as possible. A small piece will be tested for mutation&#xD;
           type.&#xD;
&#xD;
        -  If no, participants will have a small piece of tumor removed for the testing.&#xD;
&#xD;
        -  If the surgery might cure them, the participant will leave the study. The other&#xD;
           participants will be assigned to take either Sunitinib or Everolimus.&#xD;
&#xD;
        -  Participants will take their drug by mouth once a day. They will keep a medicine diary.&#xD;
           Some will keep track of their blood pressure at least weekly.&#xD;
&#xD;
        -  Screening tests may be repeated at study visits. Participants also may have their heart&#xD;
           evaluated.&#xD;
&#xD;
        -  About 30 days after the last day of their study drug, participants will have a follow-up&#xD;
           visit that repeats the screening tests.&#xD;
&#xD;
        -  Participants will be contacted every 3 months after this visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Neuroendocrine tumors (NETs) of the gastrointestinal tract and pancreas are a rare and&#xD;
           heterogeneous group of neoplasms with unique tumor biology, natural history, and&#xD;
           clinical management issues.&#xD;
&#xD;
        -  Most NETs are sporadic, but they can be part of familial cancer syndromes such as&#xD;
           multiple endocrine neoplasia type 1 (MEN1), neurofibromatosis type 1 (NF1) or Von&#xD;
           Hippel-Lindau (VHL) syndrome.&#xD;
&#xD;
        -  Well-differentiated, low or intermediate grade NETs have a heterogeneous natural&#xD;
           history.&#xD;
&#xD;
        -  Surgery is the only curative treatment option in patients with localized early stage&#xD;
           NETs.&#xD;
&#xD;
        -  The optimal management strategy for patients with advanced NETs is unknown.&#xD;
&#xD;
        -  The majority of NETs have somatic mutations in MEN1 and cyclin dependent kinase&#xD;
           inhibitor 1B (CDKN1B), and genes involved in the phosphatidylinositol-3-kinase&#xD;
           (PI3K/AKT/mammalian target of rapamycin (mTOR) signaling pathway, and/or overexpression&#xD;
           of growth factors and their receptors such as vascular endothelial growth factor (VEGF),&#xD;
           vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor&#xD;
           (PDGF), and platelet-derived growth factor receptors (PDGFR) that can be targeted for&#xD;
           therapy.&#xD;
&#xD;
        -  Survival in patients with NETs and somatic mutations is better than patients with wild&#xD;
           type NETs.&#xD;
&#xD;
        -  Sunitinib (multi-tyrosine kinase inhibitor) and Everolimus (mTOR signaling pathway&#xD;
           inhibitor) are currently approved for the treatment of progressive, unresectable,&#xD;
           locally advanced or metastatic pancreatic NETs.&#xD;
&#xD;
        -  However, mutation targeted therapy with Sunitinib or Everolimus has not been studied in&#xD;
           this patient population.&#xD;
&#xD;
        -  The present proposal aims to determine if mutation targeting therapy for patients with&#xD;
           advanced low- or intermediate grade NETs is more effective than historically expected&#xD;
           results.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      -To determine the progression-free survival in patients with NETs of the gastrointestinal&#xD;
      tract and pancreas treated with Sunitinib or Everolimus based on tumor genotyping.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      -Patients with:&#xD;
&#xD;
        -  progressive, histologically or cytologically diagnosed low or intermediate grade locally&#xD;
           advanced or metastatic NETs.&#xD;
&#xD;
        -  Age greater than or equal to 18 years&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Phase II open labeled clinical trial.&#xD;
&#xD;
        -  Tumor biopsy for tumor genotyping will be performed if the patient does not have&#xD;
           archival tissue available and does not have MEN1, VHL or NF1.&#xD;
&#xD;
        -  Patients with somatic or germline mutations in MEN1/PDGFR/KIT/FMS-like tyrosine kinase-3&#xD;
           will be treated with Sunitinib. (Arm 1)&#xD;
&#xD;
        -  Patients with somatic/germline mutations in NF1/PTEN/PI3K/AKT/mTOR/VHL will be treated&#xD;
           with Everolimus. (Arm 2)&#xD;
&#xD;
        -  Patients with wildtype tumor will be treated with Sunitinib. (Arm 1)&#xD;
&#xD;
        -  Patients who have disease-progression on either Sunitinib or Everolimus will cross-over&#xD;
           to the other drug.&#xD;
&#xD;
        -  Treatment will continue until disease progression, unacceptable toxicity, or consent&#xD;
           withdrawal.&#xD;
&#xD;
        -  Up to 120 patients will be accrued to the study. It is anticipated that 20-30 patients&#xD;
           per year may enroll into this trial; thus accrual may be completed in 4-5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study closed due to poor accrual.&#xD;
  </why_stopped>
  <start_date type="Actual">April 8, 2015</start_date>
  <completion_date type="Actual">May 22, 2019</completion_date>
  <primary_completion_date type="Actual">May 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Amount of Time Subject Survives Without Disease Progression After Treatment</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>Median amount of time subject survives without disease progression after treatment. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Overall Response</measure>
    <time_frame>Every 3 months until disease progression, up to 12 months</time_frame>
    <description>Overall response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) is defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD). Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD) (e.g. appearance of one or more new lesions), taking as reference the smallest sum of diameters while on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>Overall survival is defined as the time from treatment start date until date of death or date last known alive following therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival Time (MST)</measure>
    <time_frame>Death, an average of 12 months follow up</time_frame>
    <description>MST is the amount of time a subject survives after therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-Serious Adverse Events</measure>
    <time_frame>Date treatment consent signed to date off study approximately 49 months and 9 days.</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Neuroendocrine Carcinoma</condition>
  <condition>Neuroendocrine Neoplasms</condition>
  <condition>Carcinoma, Neuroendocrine</condition>
  <condition>Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas</condition>
  <arm_group>
    <arm_group_label>1/ Arm 1 Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2/ Arm 2 Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>37.5 mg once daily will continue until progression or unacceptable treatment-related toxicity</description>
    <arm_group_label>1/ Arm 1 Sunitinib</arm_group_label>
    <other_name>SU11248</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg daily will continue until progression or unacceptable treatment-related toxicity</description>
    <arm_group_label>2/ Arm 2 Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:&#xD;
&#xD;
          1. Progressive, histologically or cytologically diagnosed low or intermediate grade,&#xD;
             neuroendocrine tumors confirmed by the Laboratory of Pathology, National Cancer&#xD;
             Institute (NCI). Disease progression is defined according to Response Evaluation&#xD;
             Criteria in Solid Tumors (RECIST) criteria for progression of disease or any new&#xD;
             lesions seen on 68-Gallium DOTATATE within the 18 months prior to enrolment.&#xD;
&#xD;
          2. Age greater than or equal 18 years, because the incidence and prevalence of metastatic&#xD;
             pancreatic and gastrointestinal neuroendocrine tumors in the pediatric patient&#xD;
             population is exceedingly rare (children are excluded from this study, but will be&#xD;
             eligible for future pediatric trials).&#xD;
&#xD;
          3. Patients must have measurable disease according to RECIST criteria on anatomic imaging&#xD;
             studies (computed tomography (CT) scan or magnetic resonance imaging (MRI)).&#xD;
&#xD;
          4. Willingness to undergo tumor biopsy if the patient does not have a known familial&#xD;
             cancer syndrome (multiple endocrine neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL)&#xD;
             and neurofibromatosis type 1 (NF1)). Archival tissue available.&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status &lt;2.&#xD;
&#xD;
          6. Patients must have normal organ and bone marrow function as defined below:&#xD;
&#xD;
               -  hemoglobin greater than or equal 9 g/dL *&#xD;
&#xD;
               -  leukocytes greater than or equal 3,000/mcL *&#xD;
&#xD;
               -  absolute neutrophil count greater than or equal 1,500/mcL *&#xD;
&#xD;
               -  platelets greater than or equal institutional lower limit of normal&#xD;
&#xD;
               -  total bilirubin within normal institutional limits&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase&#xD;
                  (SGOT)/alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT)&#xD;
                  less than or equal 2.5 times institutional upper limit of normal&#xD;
&#xD;
             (less than or equal 5 times upper limit of normal (ULN) in patients with liver&#xD;
             metastases)&#xD;
&#xD;
             - creatinine within normal institutional limits&#xD;
&#xD;
             OR&#xD;
&#xD;
               -  creatinine clearance greater than or equal 60 mL/min/1.73 m(2) for patients with&#xD;
                  creatinine levels above institutional normal.&#xD;
&#xD;
               -  International Normalized Ratio (INR) less than or equal 2;&#xD;
&#xD;
                    -  If a patient's bone marrow function falls below the indicated values and it&#xD;
                       is not thought to be related to prior treatments a hematology consult will&#xD;
                       be ordered. If Hematology deems the patients safe to proceed with treatment&#xD;
                       they will be allowed to enroll on study. In such cases, the patients&#xD;
                       absolute neutrophil count must be greater than 1,000/mcl, hemoglobin must be&#xD;
                       greater than 7.5 g/dL and the platelet count must be &gt; 75,000 mcL. Each&#xD;
                       patient will also be seen by a medical oncologist at follow-up visits if&#xD;
                       possible.&#xD;
&#xD;
          7. Fasting serum cholesterol less than or equal 300 mg/dL OR less than or equal 7.75&#xD;
             mmol/L AND fasting triglycerides less than or equal 2.5x ULN. NOTE: In case one or&#xD;
             both of these thresholds are exceeded, the patient can only be included after&#xD;
             initiation of appropriate lipid lowering medication;&#xD;
&#xD;
          8. Women of childbearing potential (WOCBP) or partners of WOCBP participating in this&#xD;
             study must agree to use highly effective contraception while on treatment and for at&#xD;
             least 8 weeks after end of treatment, because the effects of Sunitinib and Everolimus&#xD;
             on the developing human fetus are unknown. Should a woman become pregnant or suspect&#xD;
             she is pregnant while she or her partner is participating in this study, she should&#xD;
             inform her treating physician immediately.&#xD;
&#xD;
             Highly effective contraception methods include combination of:&#xD;
&#xD;
               1. Any two of the following:&#xD;
&#xD;
                    -  Use of oral, injected or implanted hormonal methods of contraception or;&#xD;
&#xD;
                    -  Placement of an intrauterine device (IUD) or intrauterine system (IUS);&#xD;
&#xD;
                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                       cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal&#xD;
                       suppository;&#xD;
&#xD;
               2. Total abstinence or;&#xD;
&#xD;
               3. Male/female sterilization.&#xD;
&#xD;
             Women are considered post-menopausal and not of child-bearing potential if they have&#xD;
             had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile&#xD;
             (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral&#xD;
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior&#xD;
             to enrollment. In the case of oophorectomy alone, only when the reproductive status of&#xD;
             the woman has been confirmed by follow up hormone level assessment is she considered&#xD;
             not of child-bearing potential.&#xD;
&#xD;
          9. Must have fully recovered from toxicities of any prior treatment with cytotoxic drugs,&#xD;
             radiotherapy, surgery, or other anti-cancer modalities (returned to baseline status as&#xD;
             noted before most recent treatment or less than or equal grade 1).&#xD;
&#xD;
         10. Ability of subject to understand and the willingness to sign a written informed&#xD;
             consent document.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;150/100 mmHg).&#xD;
&#xD;
          -  Prior external beam radiation therapy to the target lesion(s) within 1 months prior to&#xD;
             enrollment&#xD;
&#xD;
          -  Prior systemic chemotherapy or therapy with one of the investigational agents within 1&#xD;
             month prior to enrollment.&#xD;
&#xD;
          -  Patients who had therapy with one of the investigational agents more than 1 month&#xD;
             prior to enrollment in whom tumor genotyping show assignment to the same&#xD;
             investigational agent.&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents.&#xD;
&#xD;
          -  Patients with known brain metastases will be excluded from this clinical trial because&#xD;
             of their poor prognosis and because they often develop progressive neurologic&#xD;
             dysfunction that would confound the evaluation of neurologic and other adverse events.&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to Sunitinib or Everolimus.&#xD;
&#xD;
          -  Patients who have any severe and/or uncontrolled medical conditions such as:&#xD;
&#xD;
               1. unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction less than or equal 6 months prior to start of Everolimus, serious&#xD;
                  uncontrolled cardiac arrhythmia, or any other clinically significant cardiac&#xD;
                  disease&#xD;
&#xD;
               2. symptomatic congestive heart failure of New York heart Association Class III or&#xD;
                  IV&#xD;
&#xD;
               3. active (acute or chronic) or uncontrolled severe infection, liver disease such as&#xD;
                  cirrhosis, decompensated liver disease&#xD;
&#xD;
               4. known severely impaired lung function&#xD;
&#xD;
               5. Corrected QT interval (QTc) interval &gt; 450 msec for males or &gt; 470 msec for&#xD;
                  females&#xD;
&#xD;
               6. active, bleeding diathesis;&#xD;
&#xD;
               7. psychiatric illness/social situations that would preclude informed consent, limit&#xD;
                  compliance with study requirements&#xD;
&#xD;
          -  Pregnant or nursing patients will be excluded from the study, because the effects of&#xD;
             Sunitinib and Everolimus on the developing human fetus are unknown. Because there is&#xD;
             an unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with Sunitinib or Everolimus, breastfeeding should be&#xD;
             discontinued if the mother is treated with Sunitinib or Everolimus.&#xD;
&#xD;
          -  Current treatment with therapeutic doses of Coumadin-derivative anticoagulants (low&#xD;
             dose Coumadin up to 2 mg by mouth (PO) daily for deep vein thrombosis prophylaxis is&#xD;
             allowed).&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible because of the potential for pharmacokinetic interactions with&#xD;
             study agents.&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or malabsorption&#xD;
             syndrome, or the inability to take oral medication&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HbA1c) &gt;8% despite&#xD;
             adequate therapy. Patients with a known history or diagnosis of diabetes mellitus who&#xD;
             are on therapy and have had good blood sugar control may be included, even if the&#xD;
             HbA1c is &gt; 8% because this value can take up to 3-4 months to normalize&#xD;
&#xD;
          -  Patients who have received live attenuated vaccines within 1 week of start of&#xD;
             Everolimus and during the study. Patient should also avoid close contact with others&#xD;
             who have received live attenuated vaccines. Examples of live attenuated vaccines&#xD;
             include intranasal influenza, measles, mumps, rubella, oral polio, Bacille&#xD;
             Calmette-Guerin (BCG), yellow fever, varicella and TY21a typhoid vaccines&#xD;
&#xD;
          -  Patients who are on chronic treatment with corticosteroids or other immunosuppressive&#xD;
             agents (topical or inhaled corticosteroids are allowed)&#xD;
&#xD;
          -  Patients with a history of non-compliance to medical regimens or who are considered&#xD;
             potentially unreliable or will not be able to complete the entire study&#xD;
&#xD;
          -  Patients who are taking medications that are strong inhibitors of cytochrome P450 AA4&#xD;
             (CYP3A4) or PgP and need to remain on these medications. For a current table of&#xD;
             Substrates, Inhibitors and Inducers please access the following&#xD;
             website:http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResourc&#xD;
             es/DrugInteractionsLabeling/ucm093664.htm&#xD;
&#xD;
          -  Patients who have a history of another primary malignancy from which the patient has&#xD;
             been disease free for &lt; 3 years at the time of enrolment, with the exceptions of: a&#xD;
             patient with a familial cancer syndrome-associated NETs including MEN1, VHL, NF-1, and&#xD;
             tuberous sclerosis (TS);&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naris Nilubol, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-C-0040.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Gan HK, Seruga B, Knox JJ. Sunitinib in solid tumors. Expert Opin Investig Drugs. 2009 Jun;18(6):821-34. doi: 10.1517/13543780902980171. Review.</citation>
    <PMID>19453268</PMID>
  </reference>
  <reference>
    <citation>Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol. 2008 Apr 1;26(10):1596-602. doi: 10.1200/JCO.2007.14.1127. Epub 2008 Mar 10.</citation>
    <PMID>18332467</PMID>
  </reference>
  <reference>
    <citation>Khagi S, Saif MW. Neuroendocrine tumors: treatment updates. JOP. 2013 Jul 10;14(4):367-71. doi: 10.6092/1590-8577/1657.</citation>
    <PMID>23846929</PMID>
  </reference>
  <results_reference>
    <citation>Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, Meltzer P, Pacak K, Marx S, Kebebew E. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open. 2015 May 19;5(5):e008248. doi: 10.1136/bmjopen-2015-008248.</citation>
    <PMID>25991462</PMID>
  </results_reference>
  <results_reference>
    <citation>Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Mor-Cohen R, Neychev V, Stevenson H, Keutgen XM, Patel D, Nilubol N, Meltzer P, Kebebew E. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS. Endocr Pract. 2019 Jun;25(6):580-588. doi: 10.4158/EP-2018-0603. Epub 2019 Mar 13.</citation>
    <PMID>30865533</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <results_first_submitted>April 29, 2020</results_first_submitted>
  <results_first_submitted_qc>August 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Naris Nilubol, M.D.</investigator_full_name>
    <investigator_title>National Cancer Institute</investigator_title>
  </responsible_party>
  <keyword>MEN1</keyword>
  <keyword>VHL</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>NF1</keyword>
  <keyword>mTOR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 15, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02315625/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02315625/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study closed due to poor accrual.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sunitinib Followed by Everolimus</title>
          <description>In Period 1 participants received Sunitinib 37.5 mg once daily until progression or unacceptable treatment-related toxicity. In Period 2 participants received Everolimus 10 mg daily until progression or unacceptable treatment-related toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Everolimus Followed by Sunitinib</title>
          <description>In Period 1 participants received Everolimus 10 mg daily until progression or unacceptable treatment-related toxicity. In Period 2 participants received Sunitinib 37.5 mg once daily until progression or unacceptable treatment-related toxicity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sunitinib Followed by Everolimus</title>
          <description>In Period 1 participants received Sunitinib 37.5 mg once daily until progression or unacceptable treatment-related toxicity. In Period 2 participants received Everolimus 10 mg daily until progression or unacceptable treatment-related toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Everolimus Followed by Sunitinib</title>
          <description>In Period 1 participants received Everolimus 10 mg daily until progression or unacceptable treatment-related toxicity. In Period 2 participants received Sunitinib 37.5 mg once daily until progression or unacceptable treatment-related toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.94" spread="8.49"/>
                    <measurement group_id="B2" value="53.41" spread="9.73"/>
                    <measurement group_id="B3" value="53.17" spread="9.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Amount of Time Subject Survives Without Disease Progression After Treatment</title>
        <description>Median amount of time subject survives without disease progression after treatment. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
        <time_frame>Up to approximately 2 years</time_frame>
        <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib First, Everolimus Second</title>
            <description>Participants who received Sunitinib first, followed by Everolimus.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus First, Sunitinib Second</title>
            <description>Participants who received Everolimus first, followed by Sunitinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Amount of Time Subject Survives Without Disease Progression After Treatment</title>
          <description>Median amount of time subject survives without disease progression after treatment. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progressions.</description>
          <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="15"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Overall Response</title>
        <description>Overall response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) is defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD). Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD) (e.g. appearance of one or more new lesions), taking as reference the smallest sum of diameters while on study.</description>
        <time_frame>Every 3 months until disease progression, up to 12 months</time_frame>
        <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib First, Everolimus Second</title>
            <description>Participants who received Sunitinib first, followed by Everolimus.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus First, Sunitinib Second</title>
            <description>Participants who received Everolimus first, followed by Sunitinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Overall Response</title>
          <description>Overall response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) is defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD). Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD) (e.g. appearance of one or more new lesions), taking as reference the smallest sum of diameters while on study.</description>
          <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival is defined as the time from treatment start date until date of death or date last known alive following therapy.</description>
        <time_frame>Up to approximately 4 years</time_frame>
        <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib First, Everolimus Second</title>
            <description>Participants who received Sunitinib first, followed by Everolimus.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus First, Sunitinib Second</title>
            <description>Participants who received Everolimus first, followed by Sunitinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall survival is defined as the time from treatment start date until date of death or date last known alive following therapy.</description>
          <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" lower_limit="6" upper_limit="39"/>
                    <measurement group_id="O2" value="10.7" lower_limit="0.427397" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival Time (MST)</title>
        <description>MST is the amount of time a subject survives after therapy.</description>
        <time_frame>Death, an average of 12 months follow up</time_frame>
        <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib First, Everolimus Second</title>
            <description>Participants who received Sunitinib first, followed by Everolimus.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus First, Sunitinib Second</title>
            <description>Participants who received Everolimus first, followed by Sunitinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Survival Time (MST)</title>
          <description>MST is the amount of time a subject survives after therapy.</description>
          <population>The data in this outcome measure is reported per sequence as pre-specified in the protocol.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="0.4927" upper_limit="33"/>
                    <measurement group_id="O2" value="5.5" lower_limit="0" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study approximately 49 months and 9 days.</time_frame>
        <population>One participant did not receive Sunitinib and 5 did not receive Everolimus.</population>
        <group_list>
          <group group_id="O1">
            <title>Sunitinib</title>
            <description>Participants who received Sunitinib in period 1 or 2.</description>
          </group>
          <group group_id="O2">
            <title>Everolimus</title>
            <description>Participants who received Everolimus in period 1 or 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-Serious Adverse Events</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <population>One participant did not receive Sunitinib and 5 did not receive Everolimus.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study on up to 30 days after treatment discontinuation, approximately 49 months and 9 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sunitinib</title>
          <description>Participants who received Sunitinib in period 1 or 2.</description>
        </group>
        <group group_id="E2">
          <title>Everolimus</title>
          <description>Participants who received Everolimus in period 1 or 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastric hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, multiple myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, GI bleed, oral lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Naris Nilubol</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>240-760-6154</phone>
      <email>niluboln@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

